Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
All articles — 31720 total
BTDR has reversed the cautiously improving picture from last week: short interest is climbing again, the stock has shed 16% in seven days, and the borrowing market has tightened sharply, putting the bear case back in…
Micron Technology is caught in an unusual split: the price is falling hard on geopolitical headlines, yet the positioning structure continues to move against the bears. The stock dropped another 8% on the week and is…
SoundHound AI has now lost 22% in a month and 15% in a single week, closing at $4.88, with November 5 earnings three weeks out and the short side showing no sign of fatigue. The positioning story has been covered in…
BigBear.ai enters its October 27 earnings print with the borrow market now effectively closed, short interest still near historic highs, and options traders leaning more bullish than the stock's fundamentals…
Rocket Lab has given back most of last week's 7.7% gain in a single week, falling 14.4% to $64.22 as a broad sector selloff met a fresh round of analyst target cuts. The analyst picture is the clearest explanation for…
Hertz Global Holdings is approaching its November 5 earnings date with borrow costs surging to a new high and short interest continuing to grind upward, even as the stock sits flat on the week. The single most striking…
Ondas Inc. is now running a three-week pattern that reads more like a stress test than a stock: material corporate news, a Palantir joint venture, European aviation certification, a $56 million munitions order,…
DNP has now broken above the analyst consensus price target and paused there, with earnings three weeks out and the short-side showing no sign of rebuilding in earnest. The position on the lending side is little…
WEN heads into its November 5 earnings date with a short position that refuses to deflate, a lending market that has loosened modestly from its tightest levels, and options traders who remain stubbornly positioned for…
Modivo is a stock where the bear thesis keeps getting more expensive to own and keeps failing to pay off. The cost to carry a short in MDV has risen roughly 19% since the end of August, reaching 15.8% per annum. That…
Novavax finds itself in an odd position this week: the stock is up 13% and bears are still running the show. The plague-scare rally that drove a 20% single-day gain on October 5 has largely held this time, unlike the…
NWCL has had a bruising October, falling 35% over the past month and another 18% in the past week alone, and the borrow market has taken notice in a striking and somewhat unusual way. The most eye-catching development…
VYLR has recovered well from its post-spinoff dip, but the tenth analyst initiation this week broke ranks with the bullish consensus, adding a note of caution just as the stock approaches the mean price target. The…
REAX heads into its October 29 earnings report having shed 16% in a single week, landing at $14.04, while the one analyst who just initiated coverage this morning slapped a $40 target on the stock. That gap is the…
Vivmark Residential heads into the final three weeks before its November 4 earnings report with short sellers consolidating rebuilt positions and options sentiment nudging slightly more defensive, even as the borrow…
Bending Spoons enters the final month before its November 13 earnings with the borrow market as tight as it gets and short sellers adding positions at a pace that has become one of the more striking stories in…
INIO enters the final two weeks before its October 27 earnings report with the short build that was "deliberate" six days ago now visibly accelerating, and a fresh Morgan Stanley target cut sharpening the downside…
AADX enters its November 12 earnings window with a striking divergence: short sellers have been cutting positions sharply while the stock itself has fallen 12% in a week, leaving the setup more complicated than either…
XE has given back its entire 8% gain from the prior week and then some, falling 18% to $12.72 as Morgan Stanley trimmed its price target this morning, adding fresh Street weight to a stock that was already struggling…
Seaport Therapeutics now has a fresh buy rating from Canaccord Genuity, filed this morning, arriving into a stock that has fallen another 7% this week and 31% over the past month, with the borrow market still…
